Skip to main content
. 2019 Aug 19;34(1):224–233. doi: 10.1038/s41375-019-0539-0

Fig. 6.

Fig. 6

Comparison of Rd continuous vs MPT for PFS (a) using frailty subgroups with and without ISS stage, and comparison of Rd continuous vs MPT for OS (b) using frailty subgroups with and without ISS stage. MPT Melphalan + Prednisone + Thalidomide, PFS Progression-Free Survival, ISS International Staging System, OS Overall Survival